Allergy and Immunology
11
4
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
SHAPE Pilot Trial: Skin Health and Allergy Prevention Exposure
Feasibility Study of a New Immunoglobulin E (IgE) Assay Method
Turkish Version of the Parent-Reported Drug Hypersensitivity Quality of Life Questionnaire
Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg
Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Bern Human Organoid-Study to Study Host-microbe Interaction
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
MAPS & ITEC Cohorts: 6-8 Years Follow-up
An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy Adults
Evaluation of Immune Response in COVID-19 Patients
Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects